UroGen Pharma Ltd $ 27.26 0.49 (1.83%)
Volume:
138,767
Avg Vol (1m):
157,237
Market Cap $:
571.90 Mil
Enterprise Value $:
416.59 Mil
P/E (TTM):
0.00
P/B:
2.71
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 55.02 | ||
| Debt-to-Equity | 0.01 | ||
| Debt-to-EBITDA | -0.03 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 20.91 | ||
| Beneish M-Score | 104.38 | ||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -31114.95 | ||
| Net Margin % | -29863.79 | ||
| ROE % | -51.72 | ||
| ROA % | -48.15 | ||
| ROC (Joel Greenblatt) % | -3767.94 | ||
| 3-Year EBITDA Growth Rate | -68 | ||
| 3-Year EPS without NRI Growth Rate | -61.9 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 2.71 | ||
| EV-to-EBIT | -4.44 | ||
| EV-to-EBITDA | -4.47 | ||
| EV-to-Revenue | 1384.04 | ||
| Current Ratio | 11.35 | ||
| Quick Ratio | 11.35 | ||
| Days Inventory | 9.83 | ||
| Days Payable | 912.67 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 2.71 | ||
| Price-to-Median-PS-Value | 56.79 | ||
| Earnings Yield (Greenblatt) % | -22.46 |